AbbVie Inc. $ABBV Shares Purchased by Schroder Investment Management Group

Schroder Investment Management Group boosted its stake in AbbVie Inc. (NYSE:ABBV) by 9.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,808,337 shares of the company’s stock after acquiring an additional 243,666 shares during the quarter. Schroder Investment Management Group owned about 0.16% of AbbVie worth $650,242,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in ABBV. Norges Bank purchased a new stake in AbbVie during the 2nd quarter worth $4,288,200,000. Laurel Wealth Advisors LLC grew its stake in shares of AbbVie by 18,384.4% during the second quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock valued at $1,059,141,000 after acquiring an additional 5,675,095 shares in the last quarter. Vanguard Group Inc. increased its position in shares of AbbVie by 1.9% during the second quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock worth $32,910,186,000 after acquiring an additional 3,380,842 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main increased its position in shares of AbbVie by 169.3% during the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 4,722,893 shares of the company’s stock worth $876,662,000 after acquiring an additional 2,969,202 shares during the last quarter. Finally, Raymond James Financial Inc. lifted its stake in shares of AbbVie by 41.8% in the second quarter. Raymond James Financial Inc. now owns 9,337,480 shares of the company’s stock worth $1,733,222,000 after acquiring an additional 2,753,312 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Insider Buying and Selling

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the firm’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Perry C. Siatis sold 22,381 shares of the company’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at $8,771,510. This represents a 36.98% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders own 0.08% of the company’s stock.

AbbVie Stock Performance

AbbVie stock opened at $230.41 on Monday. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The firm’s 50-day moving average is $224.72 and its 200-day moving average is $224.21. The company has a market cap of $407.40 billion, a P/E ratio of 97.63, a PEG ratio of 0.80 and a beta of 0.34.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The firm had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same quarter in the prior year, the business earned $2.16 earnings per share. AbbVie’s quarterly revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, sell-side analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $6.92 annualized dividend and a dividend yield of 3.0%. AbbVie’s dividend payout ratio (DPR) is 293.22%.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on ABBV shares. Piper Sandler raised their price objective on AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research note on Wednesday, February 18th. HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and increased their target price for the company from $225.00 to $265.00 in a research note on Wednesday, December 10th. The Goldman Sachs Group reissued a “neutral” rating and set a $223.00 price target on shares of AbbVie in a research report on Wednesday, January 28th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of AbbVie in a report on Wednesday, January 21st. Finally, Sanford C. Bernstein reiterated a “market perform” rating on shares of AbbVie in a research note on Thursday, February 5th. Two analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, AbbVie has a consensus rating of “Moderate Buy” and a consensus price target of $253.15.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.